Vergleich

Tizanidine (hydrochloride) Europäischer Partner

ArtNr HY-B0194A-100mg
Hersteller MedChem Express
CAS-Nr. 64461-82-1
Menge 100 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Kategorie
Typ Inhibitors
Specific against other
Purity 99.93
Citations [1]Kamen L, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008 Feb;24(2):425-39.
Smiles ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias 64461-82-1
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Type
Reference compound
Manufacturer - Applications
Neuroscience-Neuromodulation
Manufacturer - Targets
Adrenergic Receptor
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
290.17
Product Description
Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.Target: α2-adrenergic receptorTizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, ALS, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant. It is also prescribed for some symptoms of fibromyalgia.Tizanidine has been found to be as effective as other antispasmodic drugs and has superior tolerability to that of baclofen and diazepam. Tizanidine can be very strong even at the 2 mg dose and may cause hypotension, so caution is advised when it is used in patients who have a history of orthostatic hypotension, or when switching from gel cap to tablet form and vice versa. Tizanidine can occasionally cause liver damage, generally the hepatocellular type. Clinical trials show that up to 5% of patients treated with tizanidine had elevated liver function test values, though symptoms disappeared upon withdrawal of the drug. Care should be used when first beginning treatment with tizanidine with regular liver tests for the first 6 months of treatment.
Manufacturer - Research Area
Cancer; Neurological Disease; Endocrinology
Solubility
DMSO: 50 mg/mL (ultrasonic; warming; heat to 60°C)|H2O: 20 mg/mL (ultrasonic)
Manufacturer - Pathway
GPCR/G Protein; Neuronal Signaling
Isoform
α adrenergic receptor
Clinical information
Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen